+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Liver Fibrosis Drugs Market by Drug Type (Antifibrotic Agents, Antioxidant Inflammation Modulators, Antiviral Drugs), Distribution Channel (Offline Pharmacies, Online Pharmacies) - Forecast 2024-2030- Product Image
Global Liver Fibrosis Drugs Market by Drug Type (Antifibrotic Agents, Antioxidant Inflammation Modulators, Antiviral Drugs), Distribution Channel (Offline Pharmacies, Online Pharmacies) - Forecast 2024-2030- Product Image
Sale

Global Liver Fibrosis Drugs Market by Drug Type (Antifibrotic Agents, Antioxidant Inflammation Modulators, Antiviral Drugs), Distribution Channel (Offline Pharmacies, Online Pharmacies) - Forecast 2024-2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 4904956
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Liver Fibrosis Drugs Market size was estimated at USD 14.28 billion in 2023, USD 15.57 billion in 2024, and is expected to grow at a CAGR of 9.74% to reach USD 27.38 billion by 2030.

Liver fibrosis drugs are pharmaceutical agents designed to prevent, halt, or reverse the process of liver fibrosis. Liver fibrosis itself is a pathological condition characterized by the excessive accumulation of extracellular matrix proteins, including collagen, which leads to the scarring of liver tissue. This condition can progress to more severe forms of liver disease, such as cirrhosis and liver cancer if left untreated. These drugs aim to disrupt the fibrogenic processes, mitigate inflammation, and improve liver function. The rising incidence of conditions such as hepatitis B and C, non-alcoholic steatohepatitis (NASH), and alcoholic liver disease fuels the need for effective treatments, including liver fibrosis drugs.

Rising investments by pharmaceutical companies and research institutions for developing novel therapeutics are expanding the development of liver fibrosis drugs. The high development and production costs of liver fibrosis drugs hamper the growth of the market. The availability of international healthcare programs aimed at combating liver diseases and promoting liver health with increasing awareness and funding for liver fibrosis research and drug development are expected to create opportunities for market growth.

Regional Insights

The Americas, particularly North America, stands as a pivotal region in the development and adoption of liver fibrosis drugs. The Americas represents a significant region in pharmaceutical innovation, regulatory frameworks, and health spending, making it a primary market for liver fibrosis therapies. The high prevalence of liver diseases due to factors such as obesity and alcohol consumption further drives the need for effective treatments in this region. Additionally, strong support for liver disease research from both government and private sectors bolsters the development of new and advanced treatments for liver fibrosis.

The Asia-Pacific region is witnessing rapid growth in the liver fibrosis drug market, attributed to increasing healthcare expenditure, growing awareness of liver diseases, and improving healthcare infrastructure. Countries such as Japan, China, and South Korea are at the forefront, with Japan being a significant contributor due to its advanced healthcare system and high rate of pharmaceutical R&D. The prevalence of hepatitis B and C, major risk factors for liver fibrosis, is relatively high in this region, driving the urgency for effective treatment options. Moreover, the expanding middle-class population is increasingly able to afford advanced therapies, thereby boosting the market for liver fibrosis drugs in APAC. The EMEA region presents a diverse outlook on the market for liver fibrosis drugs. Europe is characterized by its strong regulatory frameworks, widespread healthcare access, and high awareness of liver conditions, making it a major market for these therapies. Initiatives by the European Association for the Study of the Liver (EASL) further support research and awareness, enhancing the landscape for liver fibrosis treatment. Certain countries in the Middle East are witnessing growth in healthcare infrastructure, which could lead to increased access to liver fibrosis drugs. Africa’s market growth is hindered by economic constraints, but international health organizations are stepping in to improve the situation through educational and treatment programs.

Market Trends by Segment

  • Drug Type: Growing usage of antifibrotic agents to prevent and reduce the formation of fibrosis
  • Distribution Channel: Improved access to liver fibrosis drugs due to online pharmacies 24*7 services

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Survodutide Phase II Trial Shows 83% of Adults Treated Achieved Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis

Boehringer Ingelheim has unveiled results from a Phase II clinical trial involving survodutide (BI 456906), a prospective treatment for metabolic dysfunction-associated steatohepatitis (MASH). The trial showcased that a remarkable 83.0% of adult participants receiving survodutide experienced a significant amelioration in their condition compared to a mere 18.2% in the placebo group, marking a response difference of 64.8% (with a confidence interval of 51.1% to 78.6%, and a p-value of less than 0.0001). This significant improvement was observed without any worsening in fibrosis stages F1, F2, and F3, indicating effectiveness in not just halting but potentially reversing the disease's progression. Achieving both its primary and all secondary endpoints, including notable enhancements in liver fibrosis, survodutide is now poised to redefine the treatment landscape for MASH, a disease intricately linked with a wide range of cardiovascular, renal, and metabolic disorders.

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare Cholestatic Liver Disease

Ipsen alongside GENFIT have announced the significant advancement of their new drug, elafibranor, in the regulatory process. The U.S. Food and Drug Administration (FDA) has formally accepted the New Drug Application (NDA) for elafibranor, signifying a potential breakthrough in the treatment of the rare cholestatic liver disease, Primary Biliary Cholangitis (PBC). This investigational drug, a once-daily oral dual peroxisome proliferator-activated receptor alpha/delta (PPAR α,δ) agonist, stands on the cusp of becoming the inaugural second-line therapy for PBC in nearly ten years.

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has officially accepted its New Drug Application (NDA) for resmetirom. This significant milestone targets the management of NASH with associated liver fibrosis in adult patients. Additionally, the FDA has indicated it does not foresee the necessity for an advisory committee meeting to evaluate the application, underscoring the thoroughness of the submitted documentation and the potential impact of resmetirom on treating this chronic liver condition.

Key Company Profiles

The report delves into recent significant developments in the Liver Fibrosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Arbutus Biopharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Dicerna Pharmaceuticals, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., FibroGen, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hepion Pharmaceuticals, Inc., Inventiva S.A., LG Life Science Ltd., Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Mirum Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pharmaxis Limited, and Sanofi SA.

This research report offers invaluable insights into various crucial aspects of the Liver Fibrosis Drugs Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of chronic liver diseases worldwide
5.1.1.2. Favorable reimbursement policies for treatment of liver fibrosis
5.1.2. Restraints
5.1.2.1. Complexity in formulation and development of liver fibrosis drugs
5.1.3. Opportunities
5.1.3.1. Emerging research funding for the development of novel liver fibrosis drugs
5.1.3.2. Improvements in liver imaging techniques and biomarkers for liver fibrosis
5.1.4. Challenges
5.1.4.1. Stringent regulatory frameworks for drug approval of liver fibrosis
5.2. Market Segmentation Analysis
5.2.1. Drug Type: Growing usage of antifibrotic agents to prevent and reduce the formation of fibrosis
5.2.2. Distribution Channel: Improved access to liver fibrosis drugs due to online pharmacies 24*7 services
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Liver Fibrosis Drugs Market, by Drug Type
6.1. Introduction
6.2. Antifibrotic Agents
6.3. Antioxidant Inflammation Modulators
6.4. Antiviral Drugs
6.5. Immune Modulators
7. Liver Fibrosis Drugs Market, by Distribution Channel
7.1. Introduction
7.2. Offline Pharmacies
7.3. Online Pharmacies
8. Americas Liver Fibrosis Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Liver Fibrosis Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Liver Fibrosis Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.3.1. Survodutide Phase II Trial Shows 83% of Adults Treated Achieved Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis
11.3.2. Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare Cholestatic Liver Disease
11.3.3. Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
11.4. Strategy Analysis & Recommendation
12. Competitive Portfolio
12.1. Key Company Profiles
12.2. Key Product Portfolio
List of Figures
FIGURE 1. LIVER FIBROSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. LIVER FIBROSIS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. LIVER FIBROSIS DRUGS MARKET DYNAMICS
FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 20. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. LIVER FIBROSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIFIBROTIC AGENTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIFIBROTIC AGENTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIOXIDANT INFLAMMATION MODULATORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIOXIDANT INFLAMMATION MODULATORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 30. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 31. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 32. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 33. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 34. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 37. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 38. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 39. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 40. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 41. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 42. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 43. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 44. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 45. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 46. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 47. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 48. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 49. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 50. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 51. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 52. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 53. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 54. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 55. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 56. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 57. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 58. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 59. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 60. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 61. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 62. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 63. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 64. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 65. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 66. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 67. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 68. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 70. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 72. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 74. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 76. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 77. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 78. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 79. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 80. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 81. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 82. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 83. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 84. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 85. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 86. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 87. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 88. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 89. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 90. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 91. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 92. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 93. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 94. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 95. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 96. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 97. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 98. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 99. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 100. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 101. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 102. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 103. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 104. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 105. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 106. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 107. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 108. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 109. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 110. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 111. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 112. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 113. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 114. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 115. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 116. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 117. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 118. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 119. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 120. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 121. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 122. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 123. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 124. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 125. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 126. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 127. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 128. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 129. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 130. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 131. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 132. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 133. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 134. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 135. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 136. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 137. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 138. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 139. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 140. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 141. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 142. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 143. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 144. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 145. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 146. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 147. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 148. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 157. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 158. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 159. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 160. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 161. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 162. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 163. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 164. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 165. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 166. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 167. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 168. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 169. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 170. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 171. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 172. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 173. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 174. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 175. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 176. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 177. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 178. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 179. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 180. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 181. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 182. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 183. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 184. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 185. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 186. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 187. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 188. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 189. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 190. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 191. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 192. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 193. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 194. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 195. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 196. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 197. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 198. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 199. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 200. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 201. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 202. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 203. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 204. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 205. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 206. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 207. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 208. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 209. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 210. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 211. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 212. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 213. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 214. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 215. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 216. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 217. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 218. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 219. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 220. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 221. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 222. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 223. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 224. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 225. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 226. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 227. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 228. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 229. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 230. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 231. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 232. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 233. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 234. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 236. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 238. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 240. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 242. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 244. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 246. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 247. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 248. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 249. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 250. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 251. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 252. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 253. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 254. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 255. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 256. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 257. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 258. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 259. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 260. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 261. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 262. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 263. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 264. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 265. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 266. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 267. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 268. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 269. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 270. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 278. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 280. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
TABLE 282. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
TABLE 283. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 284. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

  • Amgen Inc.
  • Arbutus Biopharma
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Dicerna Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hepion Pharmaceuticals, Inc.
  • Inventiva S.A.
  • LG Life Science Ltd.
  • Madrigal Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mirum Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pharmaxis Limited
  • Sanofi SA

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 15.57 Billion
Forecasted Market Value ( USD ) by 2030 $ 27.38 Billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Liver Fibrosis Drugs Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F - Product Image

Liver Fibrosis Drugs Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F

  • Report
  • 172 Pages
  • Global
From
Liver Fibrosis Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Liver Fibrosis Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 105 Pages
  • Global
From
Liver Fibrosis - Pipeline Insight, 2024 - Product Image

Liver Fibrosis - Pipeline Insight, 2024

  • Drug Pipelines
  • 85 Pages
  • Global
From
Liver Fibrosis Patient Pool Analysis, Market Size and Market Forecast APAC - 2034 - Product Image

Liver Fibrosis Patient Pool Analysis, Market Size and Market Forecast APAC - 2034

  • Report
  • 120 Pages
  • Asia Pacific
From
Liver Fibrosis Market Report and Forecast 2024-2032 - Product Image

Liver Fibrosis Market Report and Forecast 2024-2032

  • Report
  • 180 Pages
  • Global
From

About the Liver Fibrosis Drug Market

The Liver Fibrosis Drug market is a subset of the pharmaceutical industry focused on the development of treatments for liver fibrosis. Clinical trials are a key component of the development process, as they provide evidence of the safety and efficacy of a drug. Clinical trials are conducted in phases, with each phase providing increasingly detailed information about the drug's effects. The first phase of a clinical trial typically involves a small number of participants and is designed to assess the safety of the drug. Subsequent phases involve larger numbers of participants and are designed to assess the efficacy of the drug. The Liver Fibrosis Drug market is highly competitive, with many companies vying for a share of the market. Companies in the market include Gilead Sciences, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.